We'll know more about the company's medium-term prospects by the end of the year.

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

The company's strong cash position gives investors confidence in the gene-editing stock.

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

Buying biotech stocks is a great way to add growth to your portfolio. This particular player won approval for its first product a couple of years ago, proving the strength of its game-changing ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

For the first time, a team of researchers from Stellenbosch University (SU) and the Agricultural Research Council has ...

Cathie Wood and Wall Street don't always agree. The chief executive officer of Ark Invest has been more bullish on Tesla, for example, than the general analyst community and has taken advantage of ...

The latest health news highlights Gerresheimer's rejection of a takeover bid from Silgan, researchers' progress with CRISPR for Down syndrome, Eli Lilly's obesity pill traction, Trump's push on ...

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...

The issuer is solely responsible for the content of this announcement. BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology Newly patented CRISPR nuclease exhibits ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...